944718-09-6 Usage
General Description
2,2-Dimethyl-propionic acid 6-methoxy-1-oxo-1,3-dihydro-isoindol-2-ylmethyl ester is a complex chemical compound with several functional groups. It contains a propionic acid group and a methyl ester group, as well as a 6-methoxy-1-oxo-1,3-dihydro-isoindol-2-ylmethyl group. 2,2-DIMETHYL-PROPIONIC ACID 6-METHOXY-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YLMETHYL ESTER is likely to have significant biological activity, as the isoindol-2-ylmethyl group is similar to the structure of certain neurotransmitters and pharmaceutical drugs. The presence of the propionic acid group suggests that it may have some acidic properties and could potentially be used as a chemical intermediate in the synthesis of other compounds. Overall, this chemical appears to be a versatile and potentially useful building block for the synthesis of more complex molecules.
Check Digit Verification of cas no
The CAS Registry Mumber 944718-09-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,4,4,7,1 and 8 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 944718-09:
(8*9)+(7*4)+(6*4)+(5*7)+(4*1)+(3*8)+(2*0)+(1*9)=196
196 % 10 = 6
So 944718-09-6 is a valid CAS Registry Number.
944718-09-6Relevant articles and documents
COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
-
Paragraph 0158; 0162, (2019/12/05)
This invention relates to compounds of the Formula (I)-(IX):, as defined herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, T
COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
-
Page/Page column 101, (2010/06/11)
This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.
